Correlation Between 4D Molecular and Corvus Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both 4D Molecular and Corvus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 4D Molecular and Corvus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between 4D Molecular Therapeutics and Corvus Pharmaceuticals, you can compare the effects of market volatilities on 4D Molecular and Corvus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 4D Molecular with a short position of Corvus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of 4D Molecular and Corvus Pharmaceuticals.

Diversification Opportunities for 4D Molecular and Corvus Pharmaceuticals

0.74

Correlation Coefficient

4D Molecular  Corvus Pharmaceuticals

Poor diversification

The 3 months correlation between FDMT and Corvus is 0.74. Overlapping area represents the amount of risk that can be diversified away by holding 4D Molecular Therapeutics and Corvus Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Corvus Pharmaceuticals and 4D Molecular is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on 4D Molecular Therapeutics are associated (or correlated) with Corvus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Corvus Pharmaceuticals has no effect on the direction of 4D Molecular i.e., 4D Molecular and Corvus Pharmaceuticals go up and down completely randomly.

Pair Corralation between 4D Molecular and Corvus Pharmaceuticals

Given the investment horizon of 90 days 4D Molecular Therapeutics is expected to generate 1.24 times more return on investment than Corvus Pharmaceuticals. However, 4D Molecular is 1.24 times more volatile than Corvus Pharmaceuticals. It trades about -0.1 of its potential returns per unit of risk. Corvus Pharmaceuticals is currently generating about -0.16 per unit of risk. If you would invest  530.00  in 4D Molecular Therapeutics on December 28, 2024 and sell it today you would lose (181.00) from holding 4D Molecular Therapeutics or give up 34.15% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	98.36%
Values	Daily Returns

4D Molecular Therapeutics  vs.  Corvus Pharmaceuticals

4D Molecular Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days 4D Molecular Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Corvus Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Corvus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with 4D Molecular and Corvus Pharmaceuticals

The main advantage of trading using opposite 4D Molecular and Corvus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 4D Molecular position performs unexpectedly, Corvus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corvus Pharmaceuticals will offset losses from the drop in Corvus Pharmaceuticals' long position.

The idea behind 4D Molecular Therapeutics and Corvus Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.